HOWL
Income statement / Annual
Last year (2024), Werewolf Therapeutics, Inc.'s total revenue was $1.89 M,
a decrease of 90.55% from the previous year.
In 2024, Werewolf Therapeutics, Inc.'s net income was -$70.52 M.
See Werewolf Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$1.89 M |
$19.94 M |
$16.40 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.81 M
|
$1.76 M
|
$2.51 M
|
$0.00
|
$777.00 K
|
$463.00 K
|
| Gross Profit |
$71.00 K
|
$18.18 M
|
$13.89 M
|
$0.00
|
-$777.00 K
|
-$463.00 K
|
| Gross Profit Ratio |
0.04
|
0.91
|
0.85
|
0
|
0
|
0
|
| Research and Development Expenses |
$56.43 M
|
$41.78 M
|
$53.76 M
|
$35.27 M
|
$16.64 M
|
$6.34 M
|
| General & Administrative Expenses |
$19.05 M
|
$18.67 M
|
$17.33 M
|
$14.82 M
|
$5.76 M
|
$3.60 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$4.17 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$19.05 M
|
$18.67 M
|
$21.50 M
|
$14.82 M
|
$5.76 M
|
$3.60 M
|
| Other Expenses |
-$1.81 M
|
-$1.76 M
|
-$5.32 M
|
$0.00
|
-$777.00 K
|
$0.00
|
| Operating Expenses |
$73.67 M
|
$58.68 M
|
$69.95 M
|
$50.09 M
|
$21.63 M
|
$9.94 M
|
| Cost And Expenses |
$75.48 M
|
$60.45 M
|
$72.46 M
|
$50.09 M
|
$22.40 M
|
$9.94 M
|
| Interest Income |
$6.67 M
|
$7.42 M
|
$1.91 M
|
$104.00 K
|
$101.00 K
|
$372.00 K
|
| Interest Expense |
$4.66 M
|
$3.14 M
|
$0.00
|
$0.00
|
$0.00
|
$372.00 K
|
| Depreciation & Amortization |
$1.81 M
|
$1.76 M
|
$2.51 M
|
$216.00 K
|
$777.00 K
|
$463.00 K
|
| EBITDA |
-$64.05 M |
-$32.47 M |
-$51.30 M |
-$49.87 M |
-$14.26 M |
-$9.41 M |
| EBITDA Ratio |
-33.98
|
-1.63
|
-3.13
|
0
|
0
|
0
|
| Operating Income Ratio |
-39.04
|
-2.03
|
-3.42
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.08 M
|
$3.14 M
|
$2.25 M
|
$104.00 K
|
$7.36 M
|
-$312.00 K
|
| Income Before Tax |
-$70.52 M
|
-$37.37 M
|
-$53.81 M
|
-$49.98 M
|
-$15.04 M
|
-$10.25 M
|
| Income Before Tax Ratio |
-37.41
|
-1.87
|
-3.28
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$70.52 M
|
-$37.37 M
|
-$53.81 M
|
-$49.98 M
|
-$14.94 M
|
-$10.99 M
|
| Net Income Ratio |
-37.41
|
-1.87
|
-3.28
|
0
|
0
|
0
|
| EPS |
-1.63 |
-1.05 |
-1.86 |
-10.94 |
-0.98 |
-0.38 |
| EPS Diluted |
-1.63 |
-1.05 |
-1.86 |
-10.94 |
-0.98 |
-0.38 |
| Weighted Average Shares Out |
$43.33 M
|
$35.65 M
|
$28.86 M
|
$18.46 M
|
$28.66 M
|
$28.66 M
|
| Weighted Average Shares Out Diluted |
$43.86 M
|
$35.65 M
|
$28.86 M
|
$18.46 M
|
$28.66 M
|
$28.66 M
|
| Link |
|
|
|
|
|
|
